Christopher Palmer has been an associate editor at MDedge News since 2017. When he's not tidying grammar, he writes short pieces about breaking FDA announcements and approvals, as well as journal articles. He proudly holds a BA in English and philosophy. Follow him on Twitter @cmacmpalm.
News
Rituximab/lenalidomide similar to rituximab/chemotherapy for follicular lymphoma
- Author:
- Christopher Palmer
Although the efficacy was similar, safety differed between the two regimens.
News
Janssen submits NDA for esketamine nasal spray
- Author:
- Christopher Palmer
Esketamine has shown promise in treating refractory depression when used with an oral antidepressant.
News
Risankizumab proves more effective in psoriasis than ustekinumab
- Author:
- Christopher Palmer
Two phase 3 trials suggested that risankizumab can do more to improve quality of life, with similar safety.
News
USPSTF releases its first perinatal depression draft recommendations
- Author:
- Christopher Palmer
Certain forms of counseling interventions have shown promise in preventing perinatal depression in pregnant and postpartum women.
News
FDA approves Diacomit for Dravet syndrome
- Author:
- Christopher Palmer
Stiripentol (Diacomit) is a new way to treat this rare but potentially life-threatening form of epilepsy.
News
FDA allows marketing of TMS to treat OCD
- Author:
- Christopher Palmer
Transcranial magnetic stimulation already is approved to treat refractory major depression and migraine with aura.
News
FDA alert: Artificial heart driver linked to higher mortality
- Author:
- Christopher Palmer
A review of the Companion 2 driver system for temporary total artificial hearts showed higher mortality and...
News
FDA approves first EpiPen generic
- Author:
- Christopher Palmer
The approval is for the generic version of the most widely prescribed epinephrine autoinjector in the United States.
News
Kalydeco approved for patients aged 1-2 years
- Author:
- Christopher Palmer
Kalydeco (ivacaftor) treats the underlying cause of cystic fibrosis and previously was approved for patients aged 2 years and older.
News
Ibalizumab shows promise against MDR HIV-1
- Author:
- Christopher Palmer
Ibalizumab can not only help decrease viral loads in patients with multidrug-resistant HIV type 1, but it also can help increase CD4 counts.
News
Long-acting beta2 agonists don’t impact cardiovascular risk factors
- Author:
- Christopher Palmer
“These findings, in a large COPD database, speak against the potential negative cardiovascular effects of olodaterol, as well as those of...
News
Janssen seeks approval for split dosing of daratumumab
- Author:
- Christopher Palmer
Safety and pharmacokinetics concentrations were comparable regardless of split or single dosing of daratumumab.
News
Maternal obesity plus diabetes lead to psychiatric disorders in offspring
- Author:
- Christopher Palmer
The highest risks were for autism spectrum disorder and ADHD.
News
FDA gives Orkambi indication for younger patients
- Author:
- Christopher Palmer
Previously, the drug was indicated for certain cystic fibrosis patients aged 6 years and older, but now it is available for patients as young as 2...
News
FDA warns against azithromycin in blood or lymph node cancers
- Author:
- Christopher Palmer
Azithromycin can lead to relapse and death when used to prevent an inflammatory lung condition in patients with blood or lymph node cancers who...